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In this study, we investigated the role of PTEN (phosphatase and tensin homolog deleted on chromo-
some 10) in a platelet-activating factor (PAF)-induced experimental pulmonary tumor metastasis
model. An adenovirus carrying PTEN cDNA (Ad-PTEN) reversed PAF-induced increase in phosphor-
ylation of AKT as well as pulmonary metastasis of B16F10. PAF-induced pulmonary metastasis
was inhibited by MAPK inhibitors, but not by PI3K inhibitor. Ad-PTEN abrogated PAF-induced phos-
phorylation of MAPKs. These data indicate PTEN/MAPK pathways play a key role in PAF-induced
tumor metastasis.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Inﬂammation is being increasingly recognized as an important
component of tumorigenesis, and the causal relationship between
inﬂammation and cancer is widely accepted [1–3]. Previous re-
views have focused on various aspects of the relationship between
cancer and inﬂammation, such as the role of various inﬂammatory
cells [4,5], mediators [4,6], or signaling pathways [7] in cancer.
Platelet-activating factor (PAF), which is produced by a variety
of inﬂammatory cells, is a potent lipid mediator involved in cellular
activation, fertilization, intracellular signaling, apoptosis, and a
myriad of inﬂammatory reactions [8–11]. We have previously
demonstrated that PAF has the ability to enhance tumor growth
and metastasis [12]. Our subsequent studies have also demon-
strated that PAF exerts these effects through the activation of the
transcription factor NF-jB [13–15] and the expression of NF-jB-
dependent molecules, such as various angiogenic factors (TNF
and vascular endothelial growth factor) [16,17], matrix metallo-
proteinase-9 [18,19], and anti-apoptotic factors (Bcl-2 and Bcl-xL)chemical Societies. Published by E
ologue deleted from chromo-
gen-activated protein kinases
College, Gwangju Institute of
f Korea.[20], which play roles in tumor growth and metastasis. Our ﬁnd-
ings provided a deeper understanding of the role of inﬂammation
in tumor promotion.
PTEN (phosphatase and tensin homolog deleted on chromo-
some 10) is a dual speciﬁcity phosphatase with both lipid and pro-
tein phosphatase activities [21]. Its lipid phosphatase activity
functions as a negative regulator of PI3K by dephosphorylating
phosphatidylinositol-(3,4,5)-triphosphate (PIP3) at the D3 position
generating phosphatidylinositol-(4,5)-biphosphate (PIP2), subse-
quently decreasing PIP3 levels. Since PIP3 leads to the stimulation
of several downstream targets, including the serine/threonine pro-
tein kinase AKT (also known as protein kinase B), which is involved
in cell survival, proliferation, apoptosis prevention, tumorigenesis,
and angiogenesis [22,23], active PTEN leads to a decrease in p-AKT
levels and, consequently, downregulates cell division and upregu-
lates apoptosis. Therefore, its loss or mutation is reported to be
associated with tumor progression and formation of metastases
[24–28].
We previously reported that PAF decreases PTEN activity, which
ultimately leads to the activation of PI3K/AKT [29]. However,
whether PAF can enhance tumor metastasis through modulating
PTEN activity remains a mystery. In the present study, we explored
this question. We found that mitogen-activated protein kinases
(MAPKs), but not AKT, play a role in PAF-induced tumor metastasis
and that PTEN regulates the activation of MAPKs.lsevier B.V. All rights reserved.
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2.1. Animals
Speciﬁc pathogen-free C57BL/6 mice were obtained from the
Damul Science (Daejeon, Republic of Korea) and housed in clean,
pathogen-free rooms in an environment with controlled tempera-
ture (23 C), humidity (55%), and a 12 h light/dark cycle. All mice
were used at 6 to 7 weeks of age. All experiments were conducted
in accordance with the guidelines of the Chonnam National Uni-
versity Institutional Animal Care and Use Committee.
2.2. Cell culture
The B16F10 mouse melanoma cell line metastatic to the lungs
of C57BL/6 mice was supplied by the Tumor Repository of the Na-
tional Cancer Institute (Bethesda, MD, USA). The H1299 human
non-small cell lung cancer cell line and the NIH/3T3 mouse embry-
onic ﬁbroblast cell line were obtained from the ATCC (Rockville,
MD, USA). B16F10 and H1299 were maintained in RPMI 1640 (GIB-
CO Invitrogen, Carlsbad, CA, USA) and NIH/3T3 was maintained in
DMEM (GIBCO) supplemented with 10% (v/v) fetal bovine serum
(GIBCO) at 37 C in a humidiﬁed atmosphere of 5% CO2 and 95% air.
2.3. Reagents
PAF (1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphoryl-choline) was
purchased from Sigma (St. Louis, MO, USA). PI3K inhibitor Wort-
mannin, MEK1/2 inhibitor U0126, JNK inhibitor SP600125, and
p38 MAP kinase inhibitor SB202190 were purchased from Calbio-
chem Merck (Darmstadt, Germany). Primary antibodies against
PTEN, phospho-AKT, AKT, phospho-ERK, phospho-JNK, phospho-
p38 MAP kinase, and PI3K were purchased from Cell Signaling
Technology (Beverly, MA, USA). Anti-GAPDH antibody and PAF
receptor antagonist WEB-2086 were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA).
2.4. Western blot analysis
Lung specimens were homogenized in PhosphoSafe Extraction
Reagent (Novagen Merck, Darmstadt, Germany) with PMSF prote-
ase inhibitor (Sigma). Equal amounts of cell lysates were separated
on 10% SDS polyacrylamide gel under reducing conditions and
were transferred onto Protran Nitrocellulose Transfer Membranes
(Whatman, Dassel, Germany). The membranes were blocked for
30 min at room temperature in 5% BSA in TBS-0.1% Tween 20
and incubated for 2 h at 4 C with primary antibodies in 5% BSA
in TBS-0.1% Tween 20. The blots were washed for 30 min with
three changes of TBS-0.1% Tween 20 solution and incubated for
30 min at room temperature with HRP-conjugated anti-rabbit
IgG Ab (Santa Cruz Biotechnology). The blots were again washed,
and ﬁnally developed in LumiGLO reagent (Cell Signaling Technol-
ogy). AKT and GAPDH were used as a loading control. The density
of each band was determined using the densitometry Fluor-STM
Imager (Bio-Rad, Muncher, Germany).
2.5. Immunoprecipitation and PTEN phosphatase assay
Lung specimens were homogenized in 50 mM Hepes (pH 7.5),
150 mM NaCl, 1 mM EDTA, 10% glycerol, 1% Triton X-100, and
1 mM PMSF. For PTEN immunoprecipitation, cell lysates were incu-
bated with anti-PTEN antibody with gentle rocking overnight at
4 C and precipitated with Protein A/G PLUS-Agarose beads (Santa
Cruz Biotechnology) with gentle rocking for 3 h at 4 C. The immu-
noprecipitated beads were washed four times with low stringencywash buffer [20 mM Hepes (pH 7.7), 50 mM NaCl, 0.1 mM EDTA,
2.5 mM MgCl2] and once with reaction buffer without substrate
[100 mM Tris–HCl (pH 8.0), 10 mM DTT]. The immunoprecipitates
were then incubated in 25 ll of reaction buffer with 0.1 mM PIP3
substrate (Echelon Biosciences, Salt Lake City, UT, USA) at 37 C
for 30 min with occasional mixing. The beads were centrifuged,
and supernatants were transferred to 96-well plates (ﬂat bottom)
and incubated at room temperature with 100 ll of Malachite Green
Solution (Malachite Green Phosphatase Assay Kit, Echelon Biosci-
ences) for 30 min. The absorbance at 630 nm was recorded in an
ELISA plate reader. PTEN phosphatase activity was calculated with
a standard curve according to the manufacturer’s instructions.
2.6. PI3K activity assay
Lung specimens were homogenized in 20 mM Tris–HCl (pH 7.4),
137 mMNaCl, 1 mMMgCl2, 1 mM CaCl2, 0.1 mM sodium orthovan-
adate, 1% Nonidet P-40, and 1 mM PMSF. Cell lysates were
incubated with anti-PI3K antibody, incubated with Protein A/G
PLUS-Agarose, and washed with TNE buffer [10 mM Tris–HCl (pH
7.4), 150 mM NaCl, 5 mM EDTA, and 0.1 mM sodium orthovana-
date]. PI3K activity in the immunoprecipitates was analyzed with
a PI3 kinase ELISA kit (Echelon Biosciences) according to the man-
ufacturer’s instructions.
2.7. Expression constructs
PTEN-pcDNA3: PTEN expression plasmid was a kind gift from Dr.
Pyoung Han Hwang (Chonbuk National University Medical School).
The PTEN plasmid comprised the wild type PTEN cDNA subcloned
into the pcDNA3 vector.
PTEN shRNA-pSUPER: For silencing the expression of PTEN, a pair
of short hairpin RNA (shRNA) targeting PTEN designed using RNAi
design software (OligoEngine, Seattle, WA, UAS). The sequence was
a 19-nt small interfering RNA (siRNA): AGGCCAACCGATACTTCTC
with a spacer sequence (TTCAAGAGA) connecting the sense and
antisense strands. To generate siRNAs, equimolar amounts of
complementary sense and antisense strands were mixed and
annealed each in a 50 ml reaction at 90 C for 4 min, 70 C for
10 min, 60 C for 30 min, 37 C for 20 min, and 25 C for 10 min.
The annealed shRNA oligos were constructed in the pSUPER vector
(OligoEngine).
Ad-PTEN: For overexpression of PTEN in the lung, adenoviral
vectors carrying PTEN gene (Ad-PTEN) and control LacZ gene
(Ad-LacZ) were a kind gift from Dr. Myung-Kwan Han (Chonbuk
National University Medical School). Ad-PTEN was created using
the GatewayTM recombination-based cloning system (Invitrogen).
pENTR-PTEN entry clone and pAd/CMV/v5 destination vector were
purchased from Invitrogen. The PTEN sequence from pENTR-PTEN
was placed into the pAd/CMV/v5 destination vector using Gateway
cloning and LR clonase by manufacturer’s instruction. pAd/CMV/
v5-PTEN was cut with Pac I and transfected into 293A cells using
Lipofectamine 2000 (Invitrogen). The next day, the media was ex-
changed, and cultured further more than 6 days. The cells were
harvested, and lysed through the repeated freeze (80 C) and
thaw (37 C). The adenoviral supernatant was further infected into
293A cells for a large scale puriﬁcation using adenovirus puriﬁca-
tion kit (Clontech, Mountain View, CA, USA).
2.8. In vitro gene transfection
H1299 cells were cultured to 50% conﬂuence in 60 mm dishes.
Cells were transfected with the empty or PTEN expression plasmid
using Lipofectamine 2000 in accordance with the manufacturer’s
recommendations. Brieﬂy, in each dish, each plasmid DNA and
2 ll Lipofectamine were separately diluted in 100 ll serum-free
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Then, the cells were refreshed with serum-free media after re-
moval of the regular supplemented media. DNA-Lipofectamine
complexes were added to each dish containing cells. Dishes were
incubated at 37 C for 6 h to allow transfection to occur, and then
growth media containing 10% serum was added. After 16 h of addi-
tional incubation, cells were treated with PAF or left untreated.
NIH/3T3 cells were transfected with the empty or PTEN shRNA
expression plasmid using Lipofectamine 2000. After transfection,
cells were selected in medium containing 500 lg/ml of G418 (GIB-
CO) for 2 weeks, and individual G418-resistant cloneswere isolated.
These clones were propagated and screened for PTEN expression via
Western blot analyses. Stable NIH/3T3 clones expressing were
maintained in medium containing 300 lg/ml of G418.
2.9. In vivo gene delivery
3  1010 plaque-forming units (PFU) Ad-PTEN or Ad-LacZ in
0.2 ml of PBS were administered intravenously into the lateral tail
vein of C57BL/6 mice 2 and/or 4 days before the injection of PAF.
2.10. Soft agar assay
2  DMEM containing 20% FBS was mixed 1:1 with 1% agar (BD
Biosciences, San Jose, CA, USA) and 5 ml of this 0.5% agar was
poured in 60 mm dishes as the agar base. 5  104 cells were sus-
pended in 0.33% top agar by mixing 0.5 ml of cells in 10% FBS with
0.5 ml of 2  DMEM supplemented with 20% FBS and 0.5 ml of 1%
agar, and pouring on top of the solidiﬁed agar base. The colonies
were allowed to grow for 2 weeks after which they were stained
with 0.1% methylene blue in 50% ethanol. Dishes were destained
by washing three times with water and lastly with 25% ethanol.
All dishes of a given experiment were analyzed for number of col-
onies of various sizes.
2.11. Lung colonization assay
B16F10 tumor cells were washed in PBS, and 1.6  105 tumor
cells (>95% viability by trypan blue exclusion assay) in 0.1 ml of
PBS were injected intravenously into the lateral tail veins of
C57BL/6 mice (n = 45 for each group). The mice were autopsied
14 days later. The lungs were removed and ﬁxed in Bouin’s solu-
tion (Sigma), and the number of surface lung colonies was counted
under a dissecting microscope [12,18].
2.12. Statistical analysis
Data are expressed as means ± S.E. Statistical signiﬁcance was
determined via one-way ANOVA (StatView; Abacus Concepts Inc.,Fig. 1. Effect of PAF on PTEN/PI3K/AKT signaling. Mice were injected intraperitoneall
phosphorylation (A) PTEN activity (B), and PI3K activity (C) were assessed via Western b
assay (n = 4 for each group of mice), respectively. (A) AKT was a loading control. (B, C) ⁄
means ± S.E.Berkeley, CA, USA). A value of P < 0.05 was regarded as statistically
signiﬁcant. All experiments were conducted at least twice.
Reproducible results were obtained and representative data are,
therefore, provided in the ﬁgures.
3. Results
3.1. PAF decreases PTEN activity and increases AKT phosphorylation
The effect of exogenous PAF on PTEN/AKT signaling was inves-
tigated in the lungs. AKT phosphorylation was increased, peaked at
20 min, and declined thereafter (Fig. 1A). PTEN activity was
decreased from 20 to 30 min post-PAF injection, and then was
restored by 60 min (Fig. 1B).
The PI3K/AKT signaling pathwaywas examined in order to eluci-
date the pathophysiological involvement of the downstream path-
way of PTEN. After the PAF (50 lg/kg) injection, PIP3 levels, which
represent PI3K activity, continued to rise and ultimately revealed a
ﬁvefold increase at 10 min andwere sustained at relatively high lev-
els for up to 60 min (Fig. 1C). The effect of PTEN on the PAF-induced
AKT activation was examined using the two cell lines, human non-
small cell lung cancer cell, H1299, and mouse embryonic ﬁbroblast
cell, NIH/3T3. H1299 and NIH/3T3 cells were transfected with
PTEN-pcDNA3 and PTEN shRNA-pSUPER vectors, respectively. As
shown in Fig 2A, PTEN was not detected in H1299 cells, and AKT
phosphorylation was increased by PAF (2 lM) at 20 min in these
cells transfected with the empty vector pcDNA3, but the PAF-in-
duced AKT phosphorylationwas abrogated by overexpressing PTEN.
In contrast, AKT phosphorylation was also observed at 20 min after
PAF treatment in PTEN-expressing NIH/3T3 cells transfected with
the empty vector pSUPER (Fig. 2B). However, AKT phosphorylation
by PAFwas induced earlier, higher and lasted longer when the PTEN
expression was knocked down using the PTEN shRNA-pSUPER vec-
tor. To test the effect of PTEN on cell proliferation and transforma-
tion, NIH/3T3 cells were plated in soft agar and allowed to grow
for 2 weeks. PTENknockdown strongly induced anchorage-indepen-
dent growth (Fig. 2C). Collectively, these data indicate that PAF de-
creases PTEN activity, which in turn, increases AKT phosphorylation.
3.2. Ad-PTEN inhibits PAF-induced experimental pulmonary
metastasis
To determine the role of PTEN in PAF-induced enhancement of
B16F10 melanoma metastasis, mice were intravenously adminis-
trated with Ad-PTEN (3  1010 PFU) or the control LacZ adenovirus
(Ad-LacZ) before PAF injection. An increase in PTEN protein expres-
sion was evident in the lungs of mice that received Ad-PTEN, but
not Ad-LacZ. This in turn led to abrogation of the PAF-induced
AKT phosphorylation (Fig. 3A) as well as restoration of they with PAF (50 lg/kg), and the lungs were obtained at the indicated times. AKT
lot analysis, PTEN phosphatase assay (n = 4 for each group of mice), and PI3K kinase
P < 0.05; ⁄⁄P < 0.001 compared with the control group. Values are expressed as the
Fig. 2. Effect of PTEN expression on the PAF-induced AKT activation. (A) H1299 cells
(4  105) were transfected with 1 lg of pcDNA3 or PTEN-pcDNA3. After 16 h, cells
were treated with 2 lM PAF for the indicated times. (B) NIH/3T3 cells (8  105)
stably expressing pSUPER or PTEN shRNA-pSUPER were treated with 2 lM PAF for
the indicated times. PTEN expression and AKT phosphorylation were detected via
Western blot analysis. GAPDH was a loading control. (C) 5  104 NIH/3T3 cells
(n = 2 for each group) were plated on soft agar. Colonies were counted 2 weeks after
plating. Values are expressed as the means ± S.E.
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B16F10 metastasis was inhibited signiﬁcantly by systemic admin-
istration of Ad-PTEN, but not by Ad-LacZ (Fig. 3C). These data
suggests that PTEN functions as a key negative regulator in PAF-
induced pulmonary metastasis.
3.3. Protein phosphatase activity of PTEN is involved in PAF-induced
tumor metastasis
PTEN is a dual speciﬁcity phosphatase with both lipid and
protein phosphatase activities [21]. Its lipid phosphatase activityfunctions as a negative regulator of PI3K/AKT pathway [30]. The
protein phosphatase activity of PTEN has been shown to inhibit
the Shc/Grb2/Sos and MAP kinase pathways [31].
To elucidate the role of lipid phosphatase activity of PTEN in
PAF-induced tumor metastasis, the mice were pretreated with
varying concentrations of Wortmannin, a PI3K inhibitor. Wortman-
nin signiﬁcantly inhibited AKT phosphorylation (Fig. 4A) and PIP3
production (Fig. 4B). However, they failed to inhibit PAF-mediated
tumor metastasis (Fig. 4C).
Therefore, we investigated the protein phosphatase activity of
PTEN. We ﬁrst examined the effect of PAF on MAPKs phosphoryla-
tion. PAF injection resulted in phosphorylation of all three MAPKs
in the lungs, peaked at 20 min, which declined thereafter (Fig. 5A).
To evaluate the relevance of MAPKs on PAF-induced enhancement
of B16F10 melanoma metastasis, mice were treated with MAPKs
inhibitors before PAF injection. As shown in Fig 5B, PAF-induced
metastasis of B16F10 was inhibited by pretreatment with MAPKs
inhibitors, U0126 (ERK inhibitor, 12 mg/kg), SP600125 (JNK inhib-
itor, 12 mg/kg), and SB202190 (p38 inhibitor, 5 mg/kg). These data
suggest that MAPKs play a key role in PAF-mediated tumor metas-
tasis. Next, we examined whether PTEN could regulate PAF-
induced MAPKs phosphorylation. Ad-PTEN, but not Ad-LacZ,
abrogated PAF-induced phosphorylation of the three MAPKs
(Fig. 6A). The effect of PTEN on the PAF-induced MAPKs activation
was also examined in two cell lines, H1299 and NIH/3T3. In the
empty vector pcDNA3-transfected H1299 cells, treatment of PAF
increased JNK and p38 MAPKs phosphorylation. However, these
PAF-induced JNK and p38 MAPKs phosphorylation was not ob-
served in the PTEN pcDNA3-transfected H1299 cells (Fig. 6B). In
the empty vector pSUPER-transfected NIH/3T3 cells, MAPKs phos-
phorylation was detected slightly after PAF treatment. However,
PAF-induced MAPKs phosphorylation was higher and lasted longer
when PTEN was knocked downwith PTEN shRNA-pSUPER (Fig. 6C).
These data suggest that PTEN negatively regulates MAPKs activa-
tion and that the protein phosphatase activity of PTEN is plays an
important role in the inhibition of PAF-mediated tumor metastasis.4. Discussion
During the past decade, in vitro and in vivo animal studies have
highlighted a potential role for PAF in tumor metastasis. We previ-
ously demonstrated that PAF enhances the pulmonary metastasis
of B16F10 and augments angiogenesis through NF-jB activation
[13–20]. In this study, we found that the PTEN/MAPK signaling
pathway is also critical in PAF-mediated tumor metastasis. This
was accomplished by demonstrating that 1) PAF decreases PTEN
activity, leading to phosphorylation of AKT as well as MAPKs, and
2) inhibitors of MAPKs, but not the PI3K inhibitors, Wortmannin,
signiﬁcantly inhibited PAF-mediated tumor metastasis.
In this study, we found that PAF injection resulted in decreased
PTEN activity, which in turn increased AKT phosphorylation. We
showed that the decreased PTEN activity played a role in the tumor
metastasis by demonstrating that systemic administration of Ad-
PTEN not only restored PAF-induced reduction in PTEN activity
but also inhibited PAF-induced tumor metastasis. We previously
showed that PAF induced decrease in PTEN activity plays a key role
in the induction of anaphylaxis [29]. Therefore, PTEN involvement
seems to be a central mechanism underlying the biological actions
of PAF.
PTEN is a dual speciﬁcity phosphatase with both lipid and pro-
tein phosphatase activities [21]. Its lipid phosphatase activity func-
tions as a negative regulator of AKT phosphorylation. PTEN
dephosphorylates PIP3 at the D3 position generating PIP2, subse-
quently decreasing PIP3 levels. Since PIP3 is required for AKT phos-
phorylation, active PTEN leads to a decrease in p-AKT levels and,
Fig. 3. Effect of PTEN on PAF-induced experimental pulmonary metastasis of B16F10 melanoma. Mice were administered intravenously with 3  1010 PFU Ad-PTEN or Ad-
LacZ 2 and 4 days prior to PAF (50 g/kg) injection. Lungs were obtained 20 min after PAF treatment. PTEN expression and AKT phosphorylation (A) and PTEN phosphatase
activity (B) were detected via Western blot analysis and PTEN phosphatase assay (n = 4 for each group of mice), respectively. (C) PAF was administered intraperitoneally for 3
consecutive days (02 days) after the injection of B16F10 cells (1.6  105). Ad-PTEN or Ad-LacZ was administered intravenously 2 and/or 4 days prior to injection with
B16F10 cells. Lungs were removed on day 14, and the numbers of surface colonies were counted (n = 5 for each group of mice). (A) GAPDH was a loading control. (B, C) ⁄,
P < 0.05 compared with the control group; #P < 0.01; ##P < 0.001 compared with the PAF-treated group. Values are expressed as the means ± S.E.
Fig. 4. Effect of PI3K inhibitors on PAF-induced experimental pulmonary metastasis of B16F10 melanoma. (A) Mice were injected intraperitoneally with PAF (50 g/kg), and
the lungs were obtained at the indicated times. AKT phosphorylation was detected via Western blot analysis. AKT was a loading control. (B) Lungs were obtained 20 min after
PAF treatment. PI3K activity was assessed via PI3K kinase assay (n = 45 for each group of mice). (C) PAF was administered intraperitoneally for 3 consecutive days (0–2 days)
after the injection of B16F10 cells (1.6  105). PI3K inhibitor Wortmannin (1 mg/kg) or PAF antagonist WEB-2086 (50 mg/kg) were administered intraperitoneally 1 h prior to
the injection of B16F10 cells. Lungs were removed on day 14, and the numbers of surface colonies were counted (n = 45 for each group of mice). ⁄, P < 0.01 compared with
the control group; ##, P < 0.01; ###, P < 0.001 compared with the PAF-treated group. Values are expressed as the means ± S.E.
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[30]. Loss of PTEN causes an increase in intracellular PIP3 levels
and activation of numerous downstream targets such as AKT,
which plays a central role in a variety of oncogenic processes
including cell growth, proliferation, apoptotic cell death, motility,
epithelial mesenchymal transition (EMT), angiogenesis, and metas-
tasis [32–34]. Therefore, the lipid phosphatase activity of PTEN has
been believed to be the most pertinent property of PTEN as a tumor
suppressor.
Based on these lines of evidence, we initially thought that PTEN
probably inhibited PAF-mediated tumor metastasis via its lipid
phosphatase activity. To elucidate the role of lipid phosphatase
activity of PTEN in PAF-induced tumor metastasis, the mice were
pretreated with the PI3K inhibitor, Wortmannin. This inhibitor sig-
niﬁcantly inhibited PAF-induced phosphorylation of AKT (Fig. 4A)
and the PIP3 production (Fig. 4B). However, the PI3K inhibitor,
Wortmannin failed to inhibit PAF-mediated tumor metastasis,
although they inhibited PAF-induced PIP3 production (Fig. 4C)
and AKT phosphorylation, suggesting that the lipid phosphatase
activity of the PTEN/AKT pathway may not be critical in this
process.Therefore, we next investigated the protein phosphatase activity
of PTEN. Given that the protein phosphatase activity of PTEN has
been shown to dephosphorylate the Shc/Grb2/Sos, which indirectly
reducing MAP kinase’s activity by reducing the phosphorylated
form of MAP kinase levels [31], we examined the relationship be-
tween PTEN and MAPKs. We found that PAF injection resulted in
phosphorylation of all three MAPKs. Overexpression of PTEN leads
to a decrease in PAF-induced three MAPKs phosphorylation
in vivo as well as in vitro (Fig. 6A and B), and PAF-induced phosphor-
ylation of the threeMAPKs as well as the basal level of MAPKs phos-
phorylation was increased when PTENwas knocked down (Fig. 6C).
This suggests that PTEN exerts protein phosphatase activity upon
MAPKs as well, in addition to lipid phosphatase activity. Impor-
tantly, PAF-induced tumor metastasis was, in contrast to PI3K
inhibitors, inhibited by MAPKs inhibitors. These data are in good
agreement with our previous report showing that the three MAPKs
played non-redundant roles in PAF-induced tumor metastasis [35].
These data further support the notion that the MAPKs, but not AKT,
play crucial roles in PAF-induced tumor metastasis.
Regarding the MAPK phosphatase activity of PTEN, it has been
reported that PTEN can dephosphorylate Shc kinase and inactivate
Fig. 5. Effect of MAPKs inhibitors on PAF-induced experimental pulmonary metastasis of B16F10 melanoma. (A) Mice were injected intraperitoneally with PAF (50 g/kg), and
the lungs were obtained at the indicated times. MAPKs phosphorylation was detected via Western blot analysis. GAPDH was a loading control. (B) PAF was treated
intraperitoneally for 3 consecutive days (0–2 days) after the injection of B16F10 cells (1.6  105). ERK inhibitor, U0126 (12 mg/kg), JNK inhibitor, SP600125 (12 mg/kg), or p38
inhibitor, SB202190 (5 mg/kg) were administered intraperitoneally 2 and 1 days prior to the injection of B16F10 cells. Lungs were removed on day 14, and the numbers of
surface colonies were counted (n = 5 for each group of mice). ⁄, P < 0.001 compared with the control group; #, P < 0.001 compared with the PAF-treated group. Values are
expressed as the means ± S.E.
Fig. 6. Effect of PTEN on PAF-induced MAPKs activation. (A) Mice were treated intraperitoneally with 3  1010 PFU Ad-PTEN or Ad-LacZ 2 and 4 days prior to PAF (50 g/kg)
injection. The lungs were obtained 20 min after PAF treatment. (B) H1299 cells (4  105) were transfected with 1 lg of pcDNA3 or PTEN-pcDNA3 vector. After 24 h, the cells
were treated with 2 lM PAF for the indicated times. (C) NIH/3T3 cells (8  105) stably expressing pSUPER or PTEN shRNA-pSUPER vector were treated with 2 lM PAF for the
indicated times. MAPKs phosphorylation was detected via Western blot analysis. GAPDH was a loading control.
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PTEN loss is reported to lead to an enhanced JNK activation, and
AKT and JNK are known to be activated independently of each
other and synergize in transformation assays [36]. This activity of
PTEN has been reported to be associated with the invasion and
migration of glioma cells [37,38]. In this study, we demonstrated
that PTEN regulates the phosphorylation of all three MAPKs in re-
sponse to PAF. Thus, we further identiﬁed PTEN as a MAPK phos-
phatase PAF-mediated tumor metastasis.
How does PAF decrease PTEN activity? The PTEN protein con-
sists of an amino-terminal phosphatase domain, a lipid-binding
C2 domain, and a 50-amino acid C-terminal domain (the ‘tail’)
of unknown function. Vazquez et al. [39] reported that the PTEN
tail is necessary for maintaining protein stability and that it also
acts to inhibit the PTEN function. Furthermore, this tail-depen-
dent regulation of stability is linked to the phosphorylation of
three residues (S380, T382, and T383) within the tail. Therefore,
phosphorylation of the tail is likely to decrease PTEN function.
We previously showed that PAF-induced PTEN phosphorylation
via increasing the activity of the protein kinase, CK2 [29], which
phosphorylates PTEN on Ser370 and Ser385 [40,41]. Therefore, it
is possible that CK2 functions as an upstream pathway of PTEN
in PAF-mediated tumor metastasis. Further studies are required
to address the underlying mechanism of how PAF activates
PTEN.In summary, we found that PAF enhances PTEN activity.
Although PTEN downregulates phospho-AKT by exerting its lipid
phosphatase activity, PTEN/AKT pathway was not involved in
PAF-mediated tumor metastasis. MAPKs are importantly involved
in PAF-induced tumor metastasis, and PTEN regulates the activa-
tion of MAPKs. Therefore, it can be concluded that PAF enhances
tumor metastasis via activating PTEN/MAPK pathways.
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